Bambusa Therapeutics Inc.
BBTXHealthcare|Biotechnology|US
$15.73
-0.12 (-0.76%)
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07717905 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU) | Chronic Spontaneous Urticaria | P1P2 | Recruiting | 48 | RCT, Double-blind | BBT001, Placebo |
| NCT07436949 A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | P1P2 | Recruiting | 64 | Double-blind | BBT002, Placebo |
| NCT06944925 A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) | Chronic Obstructive Pulmonary Disease | P1 | Recruiting | 286 | RCT, Double-blind | BBT002, Placebo |
| NCT06808477 A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) | Atopic Dermatitis | P1 | Recruiting | 237 | RCT, Double-blind | BBT001, Placebo |
| NCT07239947 A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) | Atopic Dermatitis | P1 | Recruiting | 99 | RCT, Double-blind | BBT001, Placebo |
| NCT07288554 A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Pulmonary Disease (COPD) | P1 | Recruiting | 68 | Double-blind | BBT002, Placebo |